Opus Genetics (IRD) Non-Current Debt (2025 - 2026)

Opus Genetics (IRD) posted quarterly Non-Current Debt of $1.2 million for Q1 2026, up 6.11% quarter-over-quarter from $1.1 million in Q4 2025.

Opus Genetics (IRD) Non-Current Debt (2025 - 2026) Analysis & Trends

Opus Genetics (IRD) has reported Non-Current Debt for 2 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.

In Q1 2026, Non-Current Debt changed N/A year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (changed N/A YoY), while the FY2025 annual figure was $1.1 million, changed N/A from the prior year.
Non-Current Debt advanced to $1.2 million in Q1 2026 per IRD's latest filing, from $1.1 million in the prior quarter.
Across five years, Non-Current Debt topped out at $1.2 million in Q1 2026 and bottomed at $1.0 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Opus Genetics	298.36 Mn	209.55 Mn	-	35.28 Mn

Download Data